Retension Pharmaceuticals (NASDAQ:RTSN) Stock: Insider Franklin Berger Buys 10,000 Shares

Retension Pharmaceuticals, Inc. (NASDAQ:RTSN) Director Franklin Berger purchased 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 13th. The stock was bought at an average price of $12.00 per share, for a total transaction of $120,000.00. Following the transaction, the director directly owned 10,000 shares in the company, valued at $120,000. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Retension Pharmaceuticals Trading Up 0.1%

RTSN opened at $11.64 on Thursday. Retension Pharmaceuticals, Inc. has a 52 week low of $9.66 and a 52 week high of $12.50.

Retension Pharmaceuticals Company Profile

We are a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. Our product candidate, RTN-001, is a next-generation, once-daily, oral, small molecule phosphodiesterase-5 (“PDE-5”) inhibitor designed to reduce blood pressure by potentiating nitric oxide signaling, a key mechanism underlying the development and severity of hypertension. While first-generation PDE-5 inhibitors, such as Viagra (sildenafil), were originally studied in cardiovascular indications such as hypertension and angina, we believe they did not have adequate bioavailability and tissue penetration to impact the smooth muscle cells of the central vascular and cardiac tissues and thus failed to achieve clinically meaningful reductions in blood pressure.